|Mr. Joern Aldag||CEO & Director||815.58k||N/A||1959|
|Dr. Reinhard Kandera Ph.D.||CFO & Director||577.83k||N/A||1969|
|Prof. Rolf M. Zinkernagel M.D., Ph.D.||Co-Founder||N/A||N/A||1944|
|Mr. Andreas Bergthaler||Co-Founder||N/A||N/A||N/A|
|Mr. Lukas Flatz||Co-Founder||N/A||N/A||N/A|
|Ms. Christine D. Baker M.B.A.||Chief Operating Officer||N/A||N/A||1965|
|Dr. Klaus Orlinger Ph.D.||Chief Scientific Officer||N/A||N/A||1978|
|Ms. Marine Popoff||Communications & Investor Relations Mang.||N/A||N/A||N/A|
|Mr. Matthew L. S. Beck||Exec. Director of Investor Relations||N/A||N/A||N/A|
|Mr. Michael Szumera||Exec. Director of Communications||N/A||N/A||N/A|
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
HOOKIPA Pharma Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.